Ground News

Don't Just Read the News, Understand It.

Chatham Star Tribune image

News from Chatham Star Tribune

See all of Chatham Star Tribune news coverage in one place. Discover how Chatham Star Tribune’s media bias informs their coverage and compare with thousands of other news outlets.

Overall, we’ve indexed 758 stories from Chatham Star Tribune over the past 3 months.

Chatham Star Tribune’s aggregated media bias check is Center. This is a score we've assigned by combining the media bias ratings of a Center rating from Ad Fontes Media, a Center rating from Media Bias/Fact Check .

Chatham Star Tribune’s aggregated factuality score is Very High. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Chatham Star Tribune

Where is Chatham Star Tribune located?Chatham Star Tribune's Website

Media Bias Ratings

Average Bias Rating:

Center

Center

byAd Fontes Media

Center

byMedia Bias/Fact Check

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Chatham Star Tribune News

New clinical trial aims to prevent relapse in patients with DLBCL

West Virginia · West Virginia

New clinical trial aims to prevent relapse in patients with DLBCL

79% Center coverage: 66 sources

(BPT) - For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that one in three will see their cancer return…See the Story

Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects

Novo Nordisk · Denmark

Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects

76% Center coverage: 33 sources

Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive. The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo's shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen.See the Story

ICEYE to Deliver Space-Based ISR Capability to the Royal Netherlands Air Force

Europe · Amsterdam

ICEYE to Deliver Space-Based ISR Capability to the Royal Netherlands Air Force

61% Center coverage: 31 sources

Risen Energy Highlights Advancements in Green Manufacturing, Sustainable Development and Corporate Responsibility in 2024 ESG Report

60% Center coverage: 30 sources

NINGBO, China, June 22, 2025 /PRNewswire/ -- Risen Energy Co., Ltd. (SZSE: 300118), a globally leading renewable energy company, recently released its 2024 Environmental, Social and Governance (ESG) report, themed "Powering a Better World with Clean Energy." The report highlights…Ningbo · Ningbo See the Story

Blockchain Alliance International Launches Asia-Pacific Digital Economy Initiative in Hong Kong

60% Center coverage: 30 sources

Hong Kong SAR, 23–24 June 2025Innovation · Hong Kong See the Story

Kinterra Capital Submits Proposal to Acquire 100% of New World Resources

58% Center coverage: 31 sources

TORONTO and PERTH, Australia, June 22, 2025 /PRNewswire/ - Kinterra Capital GP Corp. II ("Kinterra"), in its capacity as general partner of the Kinterra Critical Materials & Infrastructure Opportunities Fund II, LP, confirms that it has submitted a non-binding, indicative…Western Australia · Western Australia See the Story

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

62% Center coverage: 26 sources

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a global strategic collaboration with…Rotterdam, South Holland · Rotterdam See the Story

How to Borrow for College Without the Stress

75% Center coverage: 35 sources

(StatePoint) A student loan can be a valuable tool to help you earn your degree – and with the right plan, it doesn’t have to be stressful.Health · United States See the Story

EAN Congress: Frequent nightmares triple risk of early death and accelerate ageing, major study finds

66% Center coverage: 29 sources

HELSINKI, June 23, 2025 /PRNewswire/ -- New research presented today at the European Academy of Neurology (EAN) Congress 2025 reveals that frequent nightmares are associated with significantly accelerated biological ageing and a more than threefold increase in the risk of…Health · Helsinki See the Story

Breakthrough: Roche's New Hemophilia Drug Achieves Zero Bleeds in Clinical Trial, Challenges Market Leader

66% Center coverage: 24 sources

Early trial data reveals NXT007 achieved complete bleed prevention in highest dose groups. Phase III head-to-head study vs Hemlibra planned for 2026. See full results.Novo Nordisk · New Jersey See the Story

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

70% Center coverage: 26 sources

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosingNovo Nordisk · Charleston See the Story

Breaking News Topics Related to Chatham Star Tribune